コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ur hospital because of a high serum level of anti-DNA antibody.
2 /c mice transgenic for the heavy chain of an anti-DNA antibody.
3 ansgenic for the heavy chain of a pathogenic anti-DNA antibody.
4 ansgenic for the heavy chain of a pathogenic anti-DNA antibody.
5 for research and point-of-care monitoring of anti-DNA antibodies.
6 D-deficient 3H9 mice spontaneously generated anti-DNA antibodies.
7 mice) treated with pathogenic, noncomplexed anti-DNA antibodies.
8 ly on DNA-derived peptides and peptides from anti-DNA antibodies.
9 eptor is recognized by both murine and human anti-DNA antibodies.
10 ypocomplementemia, and/or elevated levels of anti-DNA antibodies.
11 ed transgenic mice whose transgenes code for anti-DNA antibodies.
12 ibrosis, deforming arthropathy and increased anti-DNA antibodies.
13 adequate predictors of the pathogenicity of anti-DNA antibodies.
15 c recipients caused a lupuslike disease with anti-DNA antibodies, an immune complex glomerulonephriti
17 plus bromocriptine led to reduced titers of anti-DNA antibodies and diminished IgG deposition in kid
18 nctional because it helps B cells to produce anti-DNA antibodies and express more CD80 (B7-1) on thei
20 antation (PBSCT) prevented the production of anti-DNA antibodies and the development of lupus nephrit
21 co-occurrence of anti-AIM2, anti-IFI16, and anti-DNA antibodies, and higher clinical measures of dis
22 e received injections of radiolabeled murine anti-DNA antibody, antibody with no DNA binding capabili
27 Significant gene up-regulation induced by anti-DNA antibodies as determined by microarray analysis
28 ficantly reduced the renal deposition of the anti-DNA antibody at 48 h (1.53%, P < 0.00001) and at 7-
29 e c-erbB2 gene product, was recognized by an anti-DNA antibody, B3, and importantly by two classical
30 antibody could provide a mechanism by which anti-DNA antibodies bind diverse host ligands, and there
31 lowing recent reports that pathogenic murine anti-DNA antibodies bind to alpha-actinin, it was obviou
32 duction of IgM, IgG, and IgA, as well as IgM anti-DNA antibodies, but was not necessary for B cell st
37 itopes in the heavy chain variable region of anti-DNA antibodies from lupus-prone (NZB/NZW F1) mice.
39 ed increases in median levels of anti-PS and anti-DNA antibodies in children with SM compared to CC (
40 pacity to quantify over the course of 30 min anti-DNA antibodies in fresh human serum without backgro
41 ing lower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal e
44 iolabeled antibody to evaluate deposition of anti-DNA antibody in the kidney and the successful use o
46 reated mice express high-affinity, unmutated anti-DNA antibodies, indicating that naive B cells that
47 found that treatment of mesangial cells with anti-DNA antibodies induced high expression of neutrophi
48 isting of the single chain Fv fragment of an anti-DNA antibody known to penetrate into living cells a
49 onitor patients with RA, 92% used either the anti-DNA antibody level or complement C3 level to monito
51 We measured anti-phosphatidylserine (PS) and anti-DNA antibody levels in 382 Ugandan children prospec
52 NA antibody-producing B cells, reduced serum anti-DNA antibody levels, retarded the development of ne
53 ertook this study to determine if pathogenic anti-DNA antibodies may also contribute to renal damage
54 ngs indicate that the renal pathogenicity of anti-DNA antibodies may be attributed in part to their a
55 ata suggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens
59 s for fluorescently stained eDNA with either anti-DNA antibodies or an ultrasensitive cell-impermeant
61 were no changes in serum levels of IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the s
64 arkedly reduced the frequency of IgG and IgG anti-DNA antibody-producing B cells, and these changes p
65 epitopes induced CD8(+) T cells that killed anti-DNA antibody-producing B cells, reduced serum anti-
67 olished key disease manifestations including anti-DNA antibody production and glomerulonephritis.
69 n complexes and autoreactive T-cell help for anti-DNA antibody production suggest novel directions fo
71 cant increase in the number of high-affinity anti-DNA antibody-secreting B cells in the spleens of E(
72 after treatment, and the frequency of Ig and anti-DNA antibody-secreting B cells was analyzed by enzy
73 ach of 3 patients, and a 10-fold decrease in anti-DNA antibody-secreting cell lines was found after t
74 ts, screening strategies now involve ANA and anti-DNA antibody testing to identify patients with so-c
75 toimmune liver disease and greater titers of anti-DNA antibodies than did males, and 2-7 times more c
76 Significantly higher renal deposition of anti-DNA antibody than of antibody without DNA binding c
77 f concept, we address a problem of detecting anti-DNA antibodies that are characteristic of systemic
78 ith mixed TCDM also reduced the formation of anti-DNA antibodies that are observed typically in male
80 h mixed TCDM also prevented the formation of anti-DNA antibodies that is typically observed in male m
81 the heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for dsDNA does
83 transgene-expressing B cells, elevated serum anti-DNA antibody titers, and glomerular immunoglobulin
84 temic lupus erythematosus, recent studies of anti-DNA antibody transgenic mice clearly demonstrate th
89 athway inhibitor were injected into mice and anti-DNA antibodies were measured by enzyme-linked immun